vs

Side-by-side financial comparison of COVENANT LOGISTICS GROUP, INC. (CVLG) and Ultragenyx Pharmaceutical Inc. (RARE). Click either name above to swap in a different company.

COVENANT LOGISTICS GROUP, INC. is the larger business by last-quarter revenue ($307.2M vs $207.3M, roughly 1.5× Ultragenyx Pharmaceutical Inc.). COVENANT LOGISTICS GROUP, INC. runs the higher net margin — 1.4% vs -62.0%, a 63.5% gap on every dollar of revenue. On growth, Ultragenyx Pharmaceutical Inc. posted the faster year-over-year revenue change (25.9% vs 14.0%). Over the past eight quarters, Ultragenyx Pharmaceutical Inc.'s revenue compounded faster (38.0% CAGR vs 3.4%).

Covenant Logistics Group, Inc. is an American company focused on truckload shipping. The company is headquartered in Chattanooga, Tennessee, and is publicly traded on the New York Stock Exchange. The company provides temperature controlled trucking, regional delivery, and longhaul team driver delivery.

Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.

CVLG vs RARE — Head-to-Head

Bigger by revenue
CVLG
CVLG
1.5× larger
CVLG
$307.2M
$207.3M
RARE
Growing faster (revenue YoY)
RARE
RARE
+11.9% gap
RARE
25.9%
14.0%
CVLG
Higher net margin
CVLG
CVLG
63.5% more per $
CVLG
1.4%
-62.0%
RARE
Faster 2-yr revenue CAGR
RARE
RARE
Annualised
RARE
38.0%
3.4%
CVLG

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
CVLG
CVLG
RARE
RARE
Revenue
$307.2M
$207.3M
Net Profit
$4.4M
$-128.6M
Gross Margin
Operating Margin
2.0%
-54.7%
Net Margin
1.4%
-62.0%
Revenue YoY
14.0%
25.9%
Net Profit YoY
-32.7%
3.5%
EPS (diluted)
$0.17
$-1.28

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CVLG
CVLG
RARE
RARE
Q1 26
$307.2M
Q4 25
$295.4M
$207.3M
Q3 25
$296.9M
$159.9M
Q2 25
$302.9M
$166.5M
Q1 25
$269.4M
$139.3M
Q4 24
$277.3M
$164.6M
Q3 24
$287.9M
$139.5M
Q2 24
$287.5M
$147.0M
Net Profit
CVLG
CVLG
RARE
RARE
Q1 26
$4.4M
Q4 25
$-128.6M
Q3 25
$9.1M
$-180.4M
Q2 25
$9.8M
$-115.0M
Q1 25
$6.6M
$-151.1M
Q4 24
$-133.2M
Q3 24
$13.0M
$-133.5M
Q2 24
$12.2M
$-131.6M
Operating Margin
CVLG
CVLG
RARE
RARE
Q1 26
2.0%
Q4 25
-8.2%
-54.7%
Q3 25
2.7%
-106.9%
Q2 25
3.8%
-64.8%
Q1 25
2.8%
-102.6%
Q4 24
3.1%
-74.3%
Q3 24
5.6%
-94.6%
Q2 24
5.4%
-79.1%
Net Margin
CVLG
CVLG
RARE
RARE
Q1 26
1.4%
Q4 25
-62.0%
Q3 25
3.1%
-112.8%
Q2 25
3.2%
-69.0%
Q1 25
2.4%
-108.5%
Q4 24
-80.9%
Q3 24
4.5%
-95.7%
Q2 24
4.2%
-89.5%
EPS (diluted)
CVLG
CVLG
RARE
RARE
Q1 26
$0.17
Q4 25
$-0.68
$-1.28
Q3 25
$0.35
$-1.81
Q2 25
$0.36
$-1.17
Q1 25
$0.24
$-1.57
Q4 24
$0.25
$-1.34
Q3 24
$0.47
$-1.40
Q2 24
$0.44
$-1.52

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CVLG
CVLG
RARE
RARE
Cash + ST InvestmentsLiquidity on hand
$421.0M
Total DebtLower is stronger
Stockholders' EquityBook value
$407.6M
$-80.0M
Total Assets
$1.0B
$1.5B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CVLG
CVLG
RARE
RARE
Q1 26
Q4 25
$4.9M
$421.0M
Q3 25
$2.7M
$202.5M
Q2 25
$143.0K
$176.3M
Q1 25
$11.2M
$127.1M
Q4 24
$35.6M
$174.0M
Q3 24
$35.2M
$150.6M
Q2 24
$1.3M
$480.7M
Total Debt
CVLG
CVLG
RARE
RARE
Q1 26
Q4 25
$261.7M
Q3 25
$233.3M
Q2 25
$245.8M
Q1 25
$216.3M
Q4 24
$221.6M
Q3 24
$231.4M
Q2 24
$235.0M
Stockholders' Equity
CVLG
CVLG
RARE
RARE
Q1 26
$407.6M
Q4 25
$404.0M
$-80.0M
Q3 25
$423.7M
$9.2M
Q2 25
$416.9M
$151.3M
Q1 25
$443.6M
$144.2M
Q4 24
$438.3M
$255.0M
Q3 24
$431.6M
$346.8M
Q2 24
$419.4M
$432.4M
Total Assets
CVLG
CVLG
RARE
RARE
Q1 26
$1.0B
Q4 25
$1.0B
$1.5B
Q3 25
$1.0B
$1.2B
Q2 25
$1.0B
$1.3B
Q1 25
$980.0M
$1.3B
Q4 24
$997.6M
$1.5B
Q3 24
$1.0B
$1.5B
Q2 24
$995.0M
$1.6B
Debt / Equity
CVLG
CVLG
RARE
RARE
Q1 26
Q4 25
0.65×
Q3 25
0.55×
Q2 25
0.59×
Q1 25
0.49×
Q4 24
0.51×
Q3 24
0.54×
Q2 24
0.56×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CVLG
CVLG
RARE
RARE
Operating Cash FlowLast quarter
$-99.8M
Free Cash FlowOCF − Capex
$-100.8M
FCF MarginFCF / Revenue
-48.6%
Capex IntensityCapex / Revenue
0.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-472.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CVLG
CVLG
RARE
RARE
Q1 26
Q4 25
$25.5M
$-99.8M
Q3 25
$41.4M
$-91.4M
Q2 25
$21.9M
$-108.3M
Q1 25
$24.8M
$-166.5M
Q4 24
$21.9M
$-79.3M
Q3 24
$56.9M
$-67.0M
Q2 24
$22.4M
$-77.0M
Free Cash Flow
CVLG
CVLG
RARE
RARE
Q1 26
Q4 25
$-3.0M
$-100.8M
Q3 25
$-7.8M
$-92.7M
Q2 25
$-14.5M
$-110.7M
Q1 25
$-8.6M
$-167.8M
Q4 24
$464.0K
$-79.5M
Q3 24
$24.3M
$-68.6M
Q2 24
$-28.1M
$-79.0M
FCF Margin
CVLG
CVLG
RARE
RARE
Q1 26
Q4 25
-1.0%
-48.6%
Q3 25
-2.6%
-58.0%
Q2 25
-4.8%
-66.5%
Q1 25
-3.2%
-120.5%
Q4 24
0.2%
-48.3%
Q3 24
8.4%
-49.2%
Q2 24
-9.8%
-53.7%
Capex Intensity
CVLG
CVLG
RARE
RARE
Q1 26
Q4 25
9.7%
0.5%
Q3 25
16.6%
0.8%
Q2 25
12.0%
1.5%
Q1 25
12.4%
1.0%
Q4 24
7.7%
0.1%
Q3 24
11.3%
1.2%
Q2 24
17.6%
1.4%
Cash Conversion
CVLG
CVLG
RARE
RARE
Q1 26
Q4 25
Q3 25
4.55×
Q2 25
2.23×
Q1 25
3.78×
Q4 24
Q3 24
4.36×
Q2 24
1.84×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CVLG
CVLG

Freight revenue$281.9M92%
Other$25.2M8%

RARE
RARE

Royalty$105.6M51%
Products$101.7M49%

Related Comparisons